Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
WALTHAM, Mass., April 04, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P. to the Company’s Board of Directors. Dr. Patel has served as a Senior Fellow at The Brookings Institution, as well as a practicing physician at Johns Hopkins since January 2011.
“Dr. Patel brings extensive leadership experience in healthcare policy, healthcare research and patient advocacy to TESARO,” said Lonnie Moulder, CEO of TESARO. “Her expertise will be a valuable resource for the Company in the current healthcare environment as we execute on our mission of providing transformative therapies to people bravely facing cancer.”
Dr. Patel has more than fifteen years of healthcare leadership experience and clinical work, with an emphasis on bridging research, innovation, policy and advocacy. Prior to joining The Brookings Institution, Dr. Patel served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House from 2009 to 2010. Prior to that, she served as Deputy Staff Director for Health for Senator Edward M. Kennedy from 2007 to 2009. Currently, Dr. Patel serves as a member of the Board of Directors of SSM Healthcare and Dignity Healthcare, which are nonprofit integrated delivery systems and Community Catalyst, a national advocacy organization. She also serves as an advisory board member for the National Commission of Physician Payment Reform, the Robert Graham Center for Policy Studies in Family Medicine and Primary Care, and the Johns Hopkins Medicine Sibley Hospital Innovation Hub. Dr. Patel earned her Bachelor of Arts degree from the University of Texas at Austin, her M.D. from the University of Texas Health Science Center, and her M.S.H.S. from the University of California, Los Angeles.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com.
Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or [email protected]
